0.025
0.00 (19.62%)
| Previous Close | 0.021 |
| Open | 0.024 |
| Volume | 5,010 |
| 52 Weeks Range |
| Operating Margin (TTM) | -10,350.57% |
| Diluted EPS (TTM) | -6.58 |
| Quarterly Revenue Growth (YOY) | -35.70% |
| Total Debt/Equity (MRQ) | 47.32% |
| Current Ratio (MRQ) | 1.28 |
| Operating Cash Flow (TTM) | -4.98 M |
| Levered Free Cash Flow (TTM) | -3.94 M |
| Return on Assets (TTM) | -115.33% |
| Return on Equity (TTM) | -714.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | Aclarion Inc | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.00 |
|
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |